# c.£1.5 million contract extension on global Phase 2 clinical trial 12 Feb 26 news # c.£1.5 million contract extension on global Phase 2 clinical trial Huntingtons Disease [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/c-1-5-million-contract-extension-on-global-phase-2-clinical-trial/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/c-1-5-million-contract-extension-on-global-phase-2-clinical-trial/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/c-1-5-million-contract-extension-on-global-phase-2-clinical-trial/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/c-1-5-million-contract-extension-on-global-phase-2-clinical-trial/) **12 February 2026, IXICO plc (AIM: IXI) – London, UK**. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world’s leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington’s Disease. The contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years. Bram Goorden, CEO of IXICO, commented: "This is another example of how IXICO’s compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease.” *The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.* [ Back to News ](/news-and-resources/news/) ### Recents ![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 2 Nov 26 news [IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/) [IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/) [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) ### Library [November 2026](/news-and-resources/news/archive/2026/11/) [October 2026](/news-and-resources/news/archive/2026/10/) [September 2026](/news-and-resources/news/archive/2026/09/) [July 2026](/news-and-resources/news/archive/2026/07/) [June 2026](/news-and-resources/news/archive/2026/06/) [May 2026](/news-and-resources/news/archive/2026/05/) [April 2026](/news-and-resources/news/archive/2026/04/) [March 2026](/news-and-resources/news/archive/2026/03/) [February 2026](/news-and-resources/news/archive/2026/02/) [January 2026](/news-and-resources/news/archive/2026/01/) [2025](/news-and-resources/news/archive/2025/) [2024](/news-and-resources/news/archive/2024/) [2023](/news-and-resources/news/archive/2023/) [2022](/news-and-resources/news/archive/2022/) [2021](/news-and-resources/news/archive/2021/) [2020](/news-and-resources/news/archive/2020/) [2019](/news-and-resources/news/archive/2019/)